Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GW786034, oral Clear all
Completed Phase 2 Interventional Results available

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

NCT01956669
View directory record Official record
Conditions
Solid Tumours
Interventions
Pazopanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
24
States / cities
Long Beach, California • Madera, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

NCT02979899
View directory record Official record
Conditions
Advanced Angiosarcoma
Interventions
TRC105, Votrient
Biological · Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
26
States / cities
Tucson, Arizona • Palo Alto, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

NCT02729194
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib, Low Fat Diet
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

NCT01262820
View directory record Official record
Conditions
Lung Cancer
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 5, 2026, 7:35 AM EDT
Terminated Phase 1 Interventional Results available

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

NCT02795819
View directory record Official record
Conditions
Renal Cell Carcinoma, Soft Tissue Sarcoma, Metastatic Disease
Interventions
AR-42, Pazopanib
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 5, 2026, 7:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

NCT01035658
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
Pazopanib, Doxil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Fort Myers, Florida • Orlando, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

NCT01506596
View directory record Official record
Conditions
Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma
Interventions
pazopanib
Drug
Lead sponsor
Vector Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Post Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

NCT03139331
View directory record Official record
Conditions
Sarcoma, Refractory Sarcoma
Interventions
Pazopanib, Irinotecan, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 5, 2026, 7:35 AM EDT
Terminated Phase 1 Interventional Results available

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

NCT01012362
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
Interventions
Pazopanib, Ixabepilone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

NCT00827372
View directory record Official record
Conditions
Lymphedema
Interventions
Pazopanib
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

NCT00861913
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Jacksonville, Florida • Detroit, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

NCT00478725
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

NCT01472081
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Pazopanib, Sunitinib, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
10
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer

NCT00367679
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Duarte, California • Rancho Mirage, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 5, 2026, 7:35 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

NCT01622660
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Pazopanib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 5, 2026, 7:35 AM EDT
Withdrawn Phase 2 Interventional

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

NCT03149120
View directory record Official record
Conditions
Soft Tissue Sarcomas
Interventions
Nivolumab, Pazopanib
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

NCT01832259
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Pazopanib, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

NCT01454804
View directory record Official record
Conditions
Advanced Cancers
Interventions
Pazopanib, Lapatinib, Trastuzumab (Herceptin®)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

NCT00732420
View directory record Official record
Conditions
Solid Tumours
Interventions
topotecan, pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

NCT01438554
View directory record Official record
Conditions
Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
Interventions
Pazopanib, GSK1120212
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors

NCT01072890
View directory record Official record
Conditions
Solid Tumors
Interventions
Temsirolimus, Pazopanib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

NCT01931098
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma, Brain Neoplasms, Central Nervous System Neoplasms
Interventions
topotecan, pazopanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

NCT02406521
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Pazopanib, Sorafenib, Radium-223
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 5, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

Pazopanib, Docetaxel, Prednisone Prostate

NCT01385228
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pazopanib, Docetaxel, Prednisone, Pegfilgrastim
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 5, 2026, 7:35 AM EDT